Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astragalus injection and Danshen injection for stable coronary heart disease
ChiCTR1900021590Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of astrgalus and salvia miltiorrhiza in coronary arteriosclerosis (4 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: hs-CRP, WBC and 6 more. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
astrgalussalvia miltiorrhiza
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900021590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021590.